Translational Medicine

08

2017-09

Continuous recruitment of multi-center clinical studies of cell immunotherapy for newly diagnosed advanced lung cancer

Led by the People's Hospital of Jiangsu Province, approved by the Health and Family Planning Commission of Jiangsu Province, and jointly carried out by multiple hospitals, the country's fir...
21

2016-09

ACTL-targeted anti-tumor cell immunotherapy combined with TKI in the treatment of advanced EGFR-sensitive mutation-positive non-small cell lung cancer: a randomized open, parallel controlled, multicen

Clinical trial contact number: 68217221/68136714/68136396/68136043/68217102 standard constrain 1. The subject or legal guardian can understand and sign the informed consent form; 2. Age from 18 to ...

<< 1 >>

Home > ACTL Immunotherapy > Translational Medicine

Committed to the research and development of products and technologies for targeted cellular immunotherapy for anti-tumor and other diseases

0755-8668-0658

info@immuclin.com

7th Floor, Building A, Tongfang Information Port, No. 11, Langshan Road, North District, Science and Technology Park, Nanshan District, Shenzhen

ACTL Immunotherapy: Functional Mechanism Advantages Safety Indications Protocols Steps Patents Translational Medicine

Treatment & Prevent: Conditions Case Studies Cooperative Hospital Early Detection Prevention Nursing & Care

About Us: Company Introduction Our Culture Milestones Qualification & Honor Team of Experts Activities Jobs Contact Us

Follow Us

Coyright © 2017 Shenzhen Immuclin Biomed, Inc. All rights reserved. 粤ICP备15002248号